Efforts Continue to Repeal Onerous R&D Amortization Rules

The Tax Relief for American Families and Workers Act of 2024 or HB 7204 was introduced that would, among other things, repeal current rules and allow a business to deduct of R&D costs in the tax year that they occur and thereby incentivize long-term investments in innovation. Such repeal has been a top policy priority…

Read More

State R&D Tax Credit to be Reestablished

A package of bills that would reestablish a state research & development (R&D) tax credit in Michigan – HBs 4368, 5099, 5100, 5101 and 5102 – passed by the Michigan Senate in bipartisan fashion 22-13 on March 19, 2024. As proposed, taxpayers and authorized businesses with 250 or more employees could claim up to $2.0…

Read More

Rare Disease Advisory Council

Legislation (HB 4167) to establish a Rare Disease Advisory Council (RDAC) in Michigan were progressing nicely through the summer following overwhelming bipartisan passage by the full House. A RDAC would empower rare disease patients as partners in helping to shape policy development relevant to the unmet needs, common struggles, and concerns on equitable, quality, and…

Read More

Regulation of Dogs and Cats in Research

SB 148 and SB 149, sponsored by Sen. Polehanki and Sen. Hertel, respectively, sought to regulate the use/disposition of animals in research including mandatory reporting on numbers of animals owned, used, and released by research facilities, mandatory requirement for adoption of research animals post-use, and other restrictions and penalties. The legislation arose after an outcry…

Read More

Legislation to Enact Prescription Drug Price Controls

SB 483, SB 484 and SB 485 were introduced in mid-September 2023 that would establish a new state board – a so-called Prescription Drug Affordability Board (PDAB) – that would determine how much pharmaceutical companies can charge for certain drugs by setting an “upper price limit”. According to PDAB supporters, such a body would lower…

Read More

So Close on Reestablishing State R&D Tax Credit…

Early fall 2023 saw a package of bills introduced that would reestablish a state research & development R&D) tax credit in Michigan – HBs 5099, 5100, 5101 and 5102. Ever since Michigan moved from the Michigan Business Tax regime to the current Corporate Income Tax regime twelve years ago, Michigan taxpayers have not been afforded…

Read More

Repeal of R&D Amortization

The America Innovation and R&D Competitiveness Act of 2023 or HB 2673 was reintroduced that would repeal current rules and allow a business to deduct of R&D costs in the tax year that they occur and thereby incentivize long-term investments in innovation. Such repeal has been a top policy priority for MichBio and the bio-industry generally…

Read More

White House Announces New Efforts to Target Prescription Drug Prices

On December 7, the Biden Administration announced new efforts intended to lower prescription drug costs. While the announcement includes broader initiatives, one component would allow invoking March-In rights under the Bayh-Dole Act to license the patent rights of drugs to other biopharmaceutical manufacturers when the price of the drug is deemed to be too high. MichBio has grave…

Read More

FTC, DOJ Finalize Merger Guidelines that Could Impede Healthcare Deals

The Federal Trade Commission (FTC) and Department of Justice (DOJ) released new merger guidelines that have implications for the life sciences industry. The new guidelines may give regulators more ammunition to go after vertical and cross-market M&A that has historically been more difficult to challenge. Private equity “roll-ups” of multiple companies may also face heightened scrutiny. The…

Read More

Drug Price Transparency Bill Introduced

HB 4409, the “Drug Manufacturer Data Reporting Act” was introduced recently by Rep. Steckloff (D-MI-19), as an attempt to seek more transparency and control of drug prices. The bill would require biotech/pharma companies to provide information on a range of expenses including R&D, marketing, clinical development, whether and how much the company received in federal…

Read More